Mark Jennings

发表

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study

D. Prais, P. Reix, H. Selvadurai, 2022, American journal of respiratory and critical care medicine.

In Vivo Administration of Tumor Necrosis Factor-α is Associated with Antiviral Activity in Human Peripheral Mononuclear Cells

E. Schlick, R. Pollard, M. Jennings, 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.